Boston Scientific Jumps On Upbeat Q2, FY22 Guidance

  • Boston Scientific Corp BSX generated net sales of $3.026 billion in Q1 FY22, beating the Wall Street estimate of $2.95 billion.
  • Sales increased 10% Y/Y on a reported basis, 12.6% on an operational basis, and 9.7% on an organic basis, better than the management estimate of approximately 5% - 8%.
  • The Company achieved an adjusted EPS of $0.39, in line with the consensus and the guidance of $0.38 - $0.40.
  • Revenues from MedSurg increased 9.1% to $1.15 billion (8% organic), Cardiovascular segment generated $1.87 billion, +11.4% (10.8% organic).
  • The adjusted gross margin expanded from 67.5% to 68.4%. It posted an adjusted operating income margin of 25.8% compared to 24.3% a year ago.
  • Outlook: Boston Scientific estimates net sales growth for Q2 of 3% - 6%, with adjusted EPS of $0.41 - $0.43, compared to the consensus of $0.44.
  • For FY22, the Company estimates sales growth of approximately 7%-9%, versus the earlier range of 6% - 8%.
  • BSX forecasts FY22 EPS of $1.74-$1.79 (prior range of $1.73 - $1.79) compared to the consensus of $1.77.
  • Price Action: BSX shares are up 2.42% at $43.63 during the market session on the last check Wednesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsNewsGuidanceHealth CareMoversTrading IdeasGeneralBriefswhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!